Objective To determine the clinical and laboratory features of immune checkpoint inhibitor (ICPI)–associated
autoimmune encephalitis (ICPI-AIE), an increasingly recognized adverse …

With the discovery that the highly effective anti-CD20 antibody therapies developed to
deplete CD20 + B cells deplete CD20 + T cells equally well, a great interest in the biological …

Smoking is a risk factor for the development and progression of multiple sclerosis (MS);
however, the pathogenic effects of smoking are poorly understood. We studied the smoking-…

Background Anti-IgLON5 disease is a rare but potentially reversible cause of cognitive
impairment, sleep disturbances, dysautonomia, and movement disorders. It is an autoimmune …

The contribution of B cells to the pathogenesis of relapsing-remitting multiple sclerosis (RRMS)
is currently of great interest due to the positive outcomes of treatment with B cell-…

In patients with multiple sclerosis (MS) and healthy controls (HC) we studied circulating MAIT
cells and MAIT cell subtypes expressing CXCR3 and CCR6 by flow cytometry. Absolute …

Background Natalizumab treatment increases the frequencies of B cells in blood but
reduces IgG in blood and CSF. Plasmablasts are important in the production of IgG, and the …

Objective: In this clinical case-control study, we investigated statin treatment in stroke patients
on a range of inflammatory effectors in peripheral blood. We focus on RhoA GTPase and …

Background Anti‐IgLON5 disease is a rare but potentially reversible cause of cognitive
impairment, sleep disturbances, dysautonomia, and movement disorders. It is a type of …

1. BACKGROUND Immune checkpoint inhibitors (CPI) have revolutionized the treatment of
oncological patients and approved by the US Food and Drug Administration for the treatment …